REGN34.SA Regeneron Pharmaceuticals, Inc.

Healthcare Biotechnology Sao Paulo Exchange
87.23 BRL
Close of Nov 5, 2026
49.90 91.89
Market cap
BRL 532B
P/E
21.0x
P/B
3.03x
ROE
15.8%
Dividend yield
0.25%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is REGN34.SA undervalued?

Graham number
Price87.23
Graham value51.90
Premium68.1%

REGN34.SA trades 68.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Regeneron Pharmaceuticals, Inc. fundamental analysis

No fundamental analysis for Regeneron Pharmaceuticals, Inc. yet.

Regeneron Pharmaceuticals, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic r…

Full company profile